Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

14 evidence topics · 11 sources

Compatible donor allocation and acceptable mismatch programs2 evidence topics · 2 sources
Kidney paired exchange1 evidence topic · 1 source
Plasma exchange and immunoadsorption2 evidence topics · 2 sources
Intravenous immunoglobulin1 evidence topic · 2 sources
B-cell-depleting antibodies1 evidence topic · 1 source
IgG-cleaving enzyme therapy2 evidence topics · 3 sources
Induction and maintenance immunosuppression1 evidence topic · 1 source
Maintenance dialysis1 evidence topic · 1 source
Limitations of current therapies3 evidence topics · 5 sources